Home » Topics » Disease categories and therapies » Neurology/psychiatric

Neurology/psychiatric
RSS

Orion and Novartis agree on the distribution of entacapone

Aug. 31, 1998

Results of phase II study support efficacy of (S)-fluoxetine as a treatment for migraine

Aug. 31, 1998

News from the ACS: Lilly investigates antioxidants for treating neuronal injury

Aug. 28, 1998

News from the ACS: Roche synthesizes selective 5-HT2C antagonists

Aug. 28, 1998

Schwarz, Discovery Therapeutics collaborate on transdermal treatment for Parkinson's disease

Aug. 27, 1998

Pierre Fabre describes antidepressant compounds with a dual mechanism of action

Aug. 27, 1998

Algos completes full NDA filing for MorphiDex

Aug. 27, 1998

Adding SIB-1508Y to antiparkinsonian therapy allows for reduction in dose of L-dopa

Aug. 27, 1998

SSRI produces significant improvements in patients with social phobia

Aug. 26, 1998

Parke-Davis synthesizes potent and selective D4 ligands with antipsychotic potential

Aug. 26, 1998

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 27, 2026.
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
Sichuan Kelun Pharmaceutical Research Institute discovers GPR6 inverse agonists
BioWorld Science
Sichuan Kelun Pharmaceutical Research Institute Co. Ltd. has identified G protein-coupled receptor 6 (GPR6) inverse agonists reported to be useful for the...
Pharma industry faces long haul to get return on investment from AI
BioWorld Science
Artificial intelligence tools are springing up at multiple points along drug discovery and development, but despite the hype, as yet there is minimal return on...